TABLE 4

Dalbavancin tissue concentrations (safety population)

TissueDalbavancin concn (mean [SD]; no. of samples) at hours (days) postdose that samples were collected:
12 (0.5)24 (1)72 (3)168 (7)240 (10)336 (14)
Plasma (μg/ml)a85.3 (18.9); 31NDbNDNDND15.3 (4.1); 31
Synovium (μg/g)c25.0 (0); 317.9 (7.8); 319.5 (4.9); 319.2 (8.9); 425.0 (0); 215.9 (7.9); 3
Synovial fluid (μg/ml)c22.9; 127.4 (10.8); 419.2 (4.9); 311.6 (3.3); 213.9 (1.0); 36.2 (1.7); 2
Bone (μg/g)6.3 (3.1); 55.0 (3.5); 54.6 (3.8); 53.8 (2.7); 53.7 (2.2); 54.1 (1.6); 5
Skin (μg/g)c19.4 (7.9); 212.5 (6.5); 313.8 (1.4); 215.7 (1.0); 221.6; 113.8 (2.1); 2
  • a Mean (SD) plasma concentrations in 31 subjects at 772 and 1,080 h were 6.2 (2.4) and 3.4 (1.7), respectively.

  • b ND, not detected.

  • c Concentrations above the upper limit of quantification are reported as 25 μg/unit.